Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier

Sponsored by Concept Medical

Spokesperson: D. Scheinert

Anchorperson: M. Leon

Summary

This EuroPCR 2025 session delivers a comprehensive update on the MagicTouch sirolimus-coated balloon (SCB) and its expanding role in treating both coronary and peripheral artery disease (CAD/PAD). The session covers the extensive clinical trial program supporting MagicTouch as a versatile treatment option across multiple indications. It highlights why sirolimus-coated balloons may offer advantages over paclitaxel-coated balloons (PCBs) for peripheral artery disease, featuring results from the first direct head-to-head randomised controlled trial. A recorded case presentation shares practical tips and insights for managing complex coronary artery disease with the sirolimus-coated balloon. Combining the latest clinical data and real-world experience, this session explores the new frontier in vascular intervention.

^{Please note that this Case-in-a-Box does not reflect the recording standards of PCR, nor does it engage our responsibility.}

Learning Objectives

To learn about the large clinical trial programme for MagicTouch sirolimus coated balloon for the treatment of coronary artery disease and how it is a versatile option across numerous indications
To understand why sirolimus coated balloon can be a better alternative for peripheral artery disease treatment from the available clinical trial data as well as results from the first head-to-head RCT against paclitaxel
To deep dive in a recorded case presentation by an expert with key tips and tricks messages for treating complex CAD with sirolimus coated balloon

Speaker

D. Scheinert

Results from the first head-to-head comparison of SCB vs. PCB in peripheral artery disease